FDA Approves GlaxoSmithKline (GSK) and Flamel Technologies (FLML) Once-a-Day COREG CR
More News related to FLML
- Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million
- Trading Radar for 11/16: Lowe's (LOW), Pacific Sunwear (PSUN), Assured Guaranty (AGO), Franklin Covey (FC) Report
- Flamel Technologies Announces Projected Release Date of Third Quarter Results; Conference Call
- Flamel Technologies Announces Licensing Agreement with Pfizer
- Baxter (BAX) and Flamel Technologies (FLML) Announce Collaboration to Formulate Longer Acting Forms of Blood Clotting Factors
More News related to GSK
- Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
- Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
- Leerink Swann Initiates Coverage on GlaxoSmithKline (GSK) with a Market Perform
- Valent Pharma (VRX) Shares Ride the Lightning, But Is the Storm Breaking? - Barron's (GSK)
More News related to FDA
- Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA)
- Needham Lifts Price Target on Dyax (DYAX) to $8
- Novo Nordisk (NVO) Atophic Vaginitis Treatment Approved by U.S. FDA
- AEterna (AEZS) Announces FDA Fast Track Status for KRX-0401
- Keryx (KERX) Granted FDA Fast Track Designation for KRX-0401
GlaxoSmithKline (NYSE: GSK) and Flamel Technologies (Nasdaq: FLML) announced FDA approval of once-a-day Coreg CR extended-release capsules, for the treatment of three cardiovascular conditions: high blood pressure, a heart attack that has reduced how well the heart pumps, Mild to severe heart failure.
COREG CR will utilize Flamel's proprietary Micropump technology, which controls the delivery of carvedilol helping to maintain appropriate amounts of medicine in the body over a 24-hour span. This technology allows COREG CR to be dosed once daily, in contrast to immediate-release COREG (carvedilol) tablets, which patients must take twice daily. GlaxoSmithKline plans to begin shipping COREG CR in the first quarter of 2007.
Related Categories
FDAStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
